baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

MOLECULAR PARTNERS N/ CH0256379097 /

2024-05-08 1:01:58 PM	Chg. +0.0600	Volume	Bid1:01:58 PM	Ask1:01:58 PM	Market Capitalization	Dividend Y.	P/E Ratio
3.2300CHF	+1.89%	32,248 Turnover: 104,615.1550	3.2100Bid Size: 22	3.2300Ask Size: 296	117.97 mill.CHF	-	-

GlobeNewswire 04-29 Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supportin...

GlobeNewswire 04-19 Life Science Cares Launches in Switzerland

GlobeNewswire 04-17 Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

GlobeNewswire 03-26 Molecular Partners Publishes Invitation to Annual General Meeting 2024

GlobeNewswire 03-14 Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

GlobeNewswire 03-01 Molecular Partners Announces Dismissal of Class Action Lawsuit

GlobeNewswire 03-01 Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and ...

GlobeNewswire 01-07 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 01-05 Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

GlobeNewswire 2023-12-14 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Co...

GlobeNewswire 2023-12-10 Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/...

GlobeNewswire 2023-11-14 Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summi...

GlobeNewswire 2023-11-03 Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) ...

GlobeNewswire 2023-11-02 Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with...

GlobeNewswire 2023-11-01 Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

GlobeNewswire 2023-10-26 Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin...

GlobeNewswire 2023-09-13 Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Ann...

GlobeNewswire 2023-08-24 Molecular Partners Reports H1 2023 Corporate Highlights and Financials

GlobeNewswire 2022-03-24 Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 ...

GlobeNewswire 2022-03-17 Molecular Partners Publishes Invitation to Annual General Meeting 2022

GlobeNewswire 2022-03-15 Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021

GlobeNewswire 2022-02-25 Molecular Partners to Present at Upcoming Healthcare Investor Conferences

GlobeNewswire 2022-02-11 Molecular Partners to Present at Upcoming Healthcare Investor Conference

GlobeNewswire 2022-02-10 Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration f...

GlobeNewswire 2022-01-18 Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19

MOLECULAR PARTNERS N/ CH0256379097 /

If you wish to receive reply to your feedback, please provide your email address.